There have been a number of developments globally in recent weeks on the AstraZeneca COVID-19 vaccine, including concerns related to vaccine-induced immune thrombotic thrombocytopenia (VITT).
The Public Health Agency of Canada prepared a short information bulletin on AstraZeneca and VITT. The bulletin compiles statements and guidance documents on these topics from a number of federal and provincial sources.